View Archive »
About The Cover
Src tyrosine kinase increases Robo1 at the plasma membrane in an Abl kinase dependent manner to promote tumor cell migration. An immunofluorescence image of endogenous Robo1 at the plasma membrane of Src transformed cells is shown. See Khusial et al (pp. 198-209) and commentary on p. 167 of this issue for details.
|
|
Table of Contents
|
| POLQ in Breast Cancer |
|
https://doi.org/10.18632/oncotarget.120
Adrian Begg
|
| 161-162 |
|
| Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker |
|
https://doi.org/10.18632/oncotarget.121
Eric O. Aboagye
|
| 163-166 |
|
| Src and Abl hijack the Robo1 pathway |
|
https://doi.org/10.18632/oncotarget.122
Christian Naus
|
| 167-167 |
Reviews
|
| Prognostic impact of the MDM2SNP309 Allele in Leukemia and Lymphoma |
|
https://doi.org/10.18632/oncotarget.123
Sean M. Post, Vinod Pant, Hussein Abbas, and Alfonso Quintás-Cardama
|
| 168-174 |
Research Papers
|
| Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients |
|
https://doi.org/10.18632/oncotarget.124
Geoff S Higgins, Adrian L Harris, Remko Prevo, Thomas Helleday, W Gillies McKenna, and Francesca M Buffa
|
| 175-184 |
|
| Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition |
|
https://doi.org/10.18632/oncotarget.125
Mounia Beloueche-Babari, Vaitha Arunan, L. Elizabeth Jackson, Nina Perusinghe, Swee Y. Sharp, Paul Workman, and Martin O. Leach
|
| 185-197 |
|
| Src activates Abl to augment Robo1 expression in order to promote tumor cell migration |
|
https://doi.org/10.18632/oncotarget.126
P. Raaj Khusial, Bhaskar Vadla, Harini Krishnan, Trudy F. Ramlall, Yongquan Shen, Hitoshi Ichikawa, Jian-Guo Geng, and Gary S. Goldberg
|
| 198-209 |
|
| Jagged1 expression regulated by Notch3 and Wnt/βcatenin signaling pathways in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.127
Xu Chen, Alexander Stoeck, Soo Jung Lee, Ie-Ming Shih, Michael M. Wang, and Tian-Li Wang
|
| 210-218 |
Research Perspectives
|
| PEAK1 a Novel Kinase Target in the Fight Against Cancer |
|
https://doi.org/10.18632/oncotarget.128
Jonathan A. Kelber, and Richard L. Klemke
|
| 219-223 |
|
| Is miR29 an oncogene or tumor suppressor in CLL |
|
https://doi.org/10.18632/oncotarget.129
Yuri Pekarsky, and Carlo M. Croce
|
| 224-227 |
|
| Targeting Rb mutant cancers by inactivating TSC2 |
|
https://doi.org/10.18632/oncotarget.130
Jennifer S. Searle, Binghui Li, and Wei Du
|
| 228-232 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC